Kiora Pharmaceuticals

KPRX

Market cap $11.3M

KPRX Hedge Fund Activity: Q1 2026 in Review

18 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2026, worth a combined $655K — down 53% from $1.39M a quarter earlier.

Fund positioning in KPRX was balanced in Q1 2026: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $57.3K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $258K sold.

• 18 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2026, down from 19 in Q4 2025.
• Funds reported $655K of Kiora Pharmaceuticals stock for Q1 2026, down 53% quarter-over-quarter.
• 7 funds opened new Kiora Pharmaceuticals positions in Q1 2026 and 7 closed out, a net change of 0 holders.
• The largest Kiora Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $57.3K added.
• The largest Kiora Pharmaceuticals seller in Q1 2026 was Stonepine Capital Management, an estimated $258K sold.

Based on aggregated 13F filings for Q1 2026.